AMGA convenes leadership groups from 16 medical organizations.

Don Wreden, M.D., president at Sutter Medical Group, stated, Our team learned a good deal. From that experience, we felt a combination of fear, pleasure, and validation for the task we have done. We anticipate working with AMGA moving forward together. Related StoriesGenetic carrier screening: an interview with Don Hardison, CEO of Great Start GeneticsRE.e., thresholds, individual attribution, risk adjustment, shared cost savings, etc. AMGA is convening two collaboratives centered on ACOs: the Advancement Collaborative and an Implementation Collaborative.Ching-Hon Pui, M.D., Dario Campana, M.D., Ph.D., Deqing Pei, M.S., W. Paul Bowman, M.D., John T. Sandlund, M.D., Sue C. Kaste, D.O., Raul C. Ribeiro, M.D., Jeffrey E. Rubnitz, M.D., Ph.D., Susana C. Raimondi, Ph.D., Mihaela Onciu, M.D., Elaine Coustan-Smith, M.S., Larry E. Kun, M.D., Sima Jeha, M.D., Cheng Cheng, Ph.D., Scott C. Howard, M.D., Vickey Simmons, R.N., Amy Bayles, C.P.N.P., Monika L. Metzger, M.D., James M. Boyett, Ph.D., Wing Leung, M.D., Ph.D., Rupert Handgretinger, M.D., James R. Downing, M.D., William E. Evans, Pharm.D., and Mary V. Relling, Pharm.D.: Treating Childhood Acute Lymphoblastic Leukemia without Cranial Irradiation Clinical trials have yielded 5-year event-free survival prices as high as 79 to 82 percent among children with acute lymphoblastic leukemia .1-3 A major challenge would be to reduce treatment-related late effects, which can occur in more than two thirds of long-term survivors.4 In an evergrowing proportion of sufferers, prophylactic cranial irradiation, once a typical treatment, is being replaced by intrathecal and systemic chemotherapy to lessen radiation-associated late complications such as second cancers, cognitive deficits, and endocrinopathy.4-8 Two pediatric medical trials tested whether prophylactic cranial irradiation could be completely omitted from treatment.9,10 Even though cumulative risks of isolated central nervous system relapse in these trials were relatively low , event-free survival rates had been only 68.4 percent and 60.7 percent, respectively.